US EditionCuris to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025
- Curis, Inc., a biotechnology company focused on emavusertib , will report its fourth quarter 2024 financial and operating results on March 31, 2025, in Lexington, Mass.
- Curis is developing emavusertib, an orally available small molecule IRAK4 inhibitor, through a 2015 collaboration with Aurigene and has exclusive rights to it.
- The management of Curis will host a conference call and simultaneous webcast on March 31, 2025, at 8:30 a.m. ET to discuss the results.
- To participate in the conference call, individuals can dial -836-8184 from the United States or -357-8785 from other locations, while a live audio webcast will be available on the investor section of the Curis website.
- Emavusertib is currently being evaluated in Phase 1/2 TakeAim studies for lymphoma and leukemia, and has received Orphan Drug Designation from the FDA for the treatment of PCNSL, AML, and MDS.
Insights by Ground AI
Does this summary seem wrong?
26 Articles
26 Articles
All
Left
1
Center
10
Right
1
The Berkshire Eagle+24 Reposted by 24 other sources
Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025
LEXINGTON, Mass., March 28, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its fourth quarter 2024 financial…
Coverage Details
Total News Sources26
Leaning Left1Leaning Right1Center10Last UpdatedBias Distribution83% Center
Bias Distribution
- 83% of the sources are Center
83% Center
C 83%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
